First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects

被引：0

作者：

Jingyi Wang ^{[1
,2
]}

Lin Wu ^{[1
]}

机构：

[1] The Second Department of Thoracic Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

[2] Xiangya Lung Cancer Center, Xiangya Hospital, Central South University

来源：

Cancer Biology & Medicine | 2024年 / 02期

关键词：

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100214 ;

摘要：

Global Cancer Statistics 2022 reported the prevalence and high mortality rate of lung cancer. Notably, non-small cell lung cancer(NSCLC) accounts for the majority of the histologic types1. Precision therapy for lung cancer has progressed rapidly and immune checkpoint inhibitors(ICIs) have become a leading research topic. Indeed, ICI therapy has been shown to improve the prognosis of lung cancer patients.

引用

页码：117 / 124

页数：8

共 50 条

[21] Immunotherapy beyond progression following first-line chemotherapy plus immunotherapy in advanced non-small cell lung cancer: A retrospective study
Gu, Xinyue
Hu, Yue
Mungur, Ishanee Devi
Gu, Feifei
Xiong, Ying
Cui, Jin
Zhong, Luhui
Zhang, Kai
Liu, Li
ONCOLOGY LETTERS, 2025, 29 (02)
[22] First-line treatment of advanced non-small cell lung cancer with ALK rearrangement: state of the art and future development
Rocco, Danilo
Della Gravara, Luigi
Battiloro, Ciro
Gridelli, Cesare
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2022, 16 (03) : 315 - 321
[23] Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer
Kish, Jonathan
Liassou, Djibril
Hartman, John
Lubinga, Solomon J.
Chopra, Dhruv
Feinberg, Bruce
AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (05): : E129 - E135
[24] Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer
Yang, Szu-Chun
Ou, Huang-Tz
Su, Wu-Chou
Wang, Shi-Yi
CANCER MEDICINE, 2023, 12 (07): : 8838 - 8850
[25] Immunological and nutritional predictors for first-line chemoimmunotherapy in advanced non-small cell lung cancer
Takeda, Takayuki
Ogura, Yuri
Kataoka, Nobutaka
Kunimatsu, Yusuke
Tachibana, Yusuke
Sugimoto, Takumi
Tani, Nozomi
Sato, Izumi
Hirose, Kazuki
Kato, Daishiro
ANNALS OF ONCOLOGY, 2021, 32 : S334 - S334
[26] Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer
Remon, Jordi
Besse, Benjamin
CURRENT OPINION IN ONCOLOGY, 2017, 29 (02) : 97 - 104
[27] Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
Fleeman, N.
Bagust, A.
McLeod, C.
Greenhalgh, J.
Boland, A.
Dundar, Y.
Dickson, R.
Smith, C. Tudur
Davis, H.
Green, J.
Pearson, M.
HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
[28] Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
Brown, T.
Boland, A.
Bagust, A.
Oyee, J.
Hockenhull, J.
Dundar, Y.
Dickson, R.
Ramani, V. S.
Proudlove, C.
HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 71 - 79
[29] Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Jahan, N.
Swarup, S.
Sultan, A.
Naing, T.
Mogollon-Duffo, F.
Ball, S.
Tun, A.
Htut, T.
Dash, A.
D'Cunha, N.
Hardwicke, F.
Awasthi, S.
Tijani, L.
Thein, K.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S917 - S918
[30] BIWEEKLY CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER
Benekli, Mustafa
Gunaydin, Yusuf
Inanc, Mevlude
Ozkan, Metin
Demirci, Ayse
Demirci, Umut
Suner, Ali
Karaca, Halit
Tonyali, Onder
Berk, Veli
Buyukberber, Suleyman
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S563 - S563

← 1 2 3 4 5 →